

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/066880 A1

(51) International Patent Classification:
A61K 31/7068 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2021/051716

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:
23 September 2021 (23.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/082,185 23 September 2020 (23.09.2020) US
63/161,055 15 March 2021 (15.03.2021) US

(71) Applicant: **TRANSPONSON THERAPEUTICS, INC.**
[US/US]; 285 Riverside Avenue, Suite 250, Westport, Con-
necticut 06880 (US).

(72) Inventor; and

(71) Applicant: **STURINO, Claudio** [CA/CA]; 158 Rue Sauve,
L'île-Bizard, Québec H9C-2Z8 (CA).


(72) Inventors: **DOSHI, Malay**; 59 Solaris Dr., Kanata, Ontario
K2M0L6 (CA). **WEBER, Eckard**; 4040 Miller Street, San
Diego, California 92103 (US). **CORDINGLEY, Michael
G.**; 320 rue Robert Ouest, Rosemère, Québec J7A1C9 (CA).

(74) Agent: **ESMOND, Robert W.** et al.; STERNE, KESSLER,
GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue,
NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: LINE-1 INHIBITORS TO TREAT DISEASE



I,

(57) Abstract: The present disclosure provides methods of treating or preventing a disease, disorder, or condition in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, wherein R¹, R², and B are defined as set forth in the specification.

WO 2022/066880 A1